Botanix Pharmaceuticals jumps on submitting New Drug Application to US FDA

Botanix Pharmaceuticals

26/09/2022 03:49

** Shares of Australia-based Botanix Pharmaceuticals
 BOT.AX  rise as much as 6.5% to A$0.066, set to gain most since
July 25, if gains hold
    ** Shares rise after the clinical dermatology company
submits application for a new drug with the U.S.
FDA(FDA) urn:newsml:reuters.com:*:nASX9xnlQb
    ** Seeks FDA approval for the drug, Sofpironium Bromide,
which treats primary axillary hyperhidrosis
    ** Perth-based co adds that it is targeting FDA approval in
4Q CY2023
    ** Stock has risen 10.7% this year, as of last close
 (Reporting by Rishav Chatterjee in Bengaluru)
 ((Rishav.Chatterjee@thomsonreuters.com;))